Cymbalta Bottles Recalled; 1 in 3 Older Adults Are Lonely; Walking Off Depression

— News and commentary from the psychiatry world

by Kristen Monaco, Senior Staff Writer, �鶹��ý December 18, 2024

Over 230,000 bottles of the antidepressant due to the presence of a potential carcinogen. (USA Today)

In an exploratory analysis of two phase III trials, in patients with acute schizophrenia and clinically significant baseline cognitive impairment. (American Journal of Psychiatry)

About one in three Americans ages 50 to 80 , the National Poll on Healthy Aging showed. (JAMA)

In a cohort study of adults with depressive symptoms, Black and Asian patients, older adults, and those screened via the patient portal compared with white patients, younger patients, and those with in-person visits. (JAMA Internal Medicine)

A higher daily step count was , a meta-analysis showed. (JAMA Network Open)

Schizophrenia and major depressive disorder , according to a Mendelian randomization analysis. (Clinical and Experimental Gastroenterology)

San Francisco , including locked beds, for people experiencing mental illness and addiction. (San Francisco Chronicle)

A fixed-dose combination of olanzapine/samidorphan (Lybalvi) with a consistent safety profile in patients with schizophrenia, schizophreniform disorder, or bipolar I disorder for up to 4 years in a phase III open-label, long-term extension trial. (Journal of Clinical Psychiatry)

The American Academy of Pediatrics on pediatric acute-onset neuropsychiatric syndrome. (Pediatrics)

The has been rising since 2021, but only among people ages 30 and older. (New York Times)

A small randomized trial in China showed that improved chronic insomnia disorder severity. (JAMA Network Open)

MindMed announced that the first-ever phase III trial of lysergide D-tartrate (LSD) is underway, testing a pharmaceutically optimized form as a . Phase IIb findings were presented earlier this year at the American Psychiatric Association annual meeting.

The American Society of Anesthesiologists released new evidence-based recommendations on strategies to reduce the risk of in older patients. (Anesthesiology)

The strongest dose of decreased Positive and Negative Syndrome Scale (PANSS) total score by 20.8 points in patients with schizophrenia at 52 weeks, said developer Reviva Pharmaceuticals.

Autism advocates are losing faith that the . (STAT)

Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.